[go: up one dir, main page]

MX2019004580A - Formulaciones farmaceuticas y metodos para prepararlas. - Google Patents

Formulaciones farmaceuticas y metodos para prepararlas.

Info

Publication number
MX2019004580A
MX2019004580A MX2019004580A MX2019004580A MX2019004580A MX 2019004580 A MX2019004580 A MX 2019004580A MX 2019004580 A MX2019004580 A MX 2019004580A MX 2019004580 A MX2019004580 A MX 2019004580A MX 2019004580 A MX2019004580 A MX 2019004580A
Authority
MX
Mexico
Prior art keywords
methods
making
same
pharmaceutical formulations
etanercept
Prior art date
Application number
MX2019004580A
Other languages
English (en)
Inventor
Goss Monica
Ball Nicole
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019004580A publication Critical patent/MX2019004580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a la formulación de composiciones farmacéuticas de etanercept. La invención también se refiere a métodos de eliminación de tampón y de formulación de composiciones farmacéuticas de etanercept.
MX2019004580A 2016-10-21 2017-10-19 Formulaciones farmaceuticas y metodos para prepararlas. MX2019004580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411458P 2016-10-21 2016-10-21
PCT/US2017/057472 WO2018075818A1 (en) 2016-10-21 2017-10-19 Pharmaceutical formulations and methods of making the same

Publications (1)

Publication Number Publication Date
MX2019004580A true MX2019004580A (es) 2019-08-12

Family

ID=61971152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004580A MX2019004580A (es) 2016-10-21 2017-10-19 Formulaciones farmaceuticas y metodos para prepararlas.

Country Status (13)

Country Link
US (5) US20180110856A1 (es)
EP (1) EP3528787B1 (es)
JP (4) JP6884858B2 (es)
KR (2) KR102446838B1 (es)
CN (2) CN109982685B (es)
AU (1) AU2017345490B2 (es)
CA (1) CA3040899A1 (es)
CL (1) CL2019001053A1 (es)
EA (1) EA201990998A1 (es)
IL (1) IL266132B (es)
MX (1) MX2019004580A (es)
SG (1) SG11201903521XA (es)
WO (1) WO2018075818A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
SG11201903521XA (en) * 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
AU2018368466B2 (en) 2017-11-17 2024-06-20 Amgen Inc. VEGFR-Fc fusion protein formulations
EP3996680A1 (en) * 2019-07-09 2022-05-18 Unichem Laboratories Ltd Stable formulations of recombinant proteins
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
JP7560038B2 (ja) * 2020-04-06 2024-10-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗体製剤
US11777543B2 (en) 2020-05-12 2023-10-03 Nec Corporation Distortion compensation apparatus and distortion compensation method

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2837168A1 (de) 1978-08-25 1980-03-06 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung einer fuer die intravenoese anwendung geeigneten immunglobulinloesung
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4396608A (en) 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4681713A (en) 1984-03-15 1987-07-21 Toyo Boseki Kabushiki Kaisha Method of making a hollow fiber membrane for dialysis
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
GB8628104D0 (en) 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3640513A1 (de) 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
JP2547556B2 (ja) 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
JP3179538B2 (ja) 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5110910A (en) 1991-03-25 1992-05-05 Miles Inc. Virucidal euglobulin precipitation
US5256571A (en) 1991-05-01 1993-10-26 Cytyc Corporation Cell preservative solution
CA2126182C (en) 1991-12-20 2001-07-17 Man S. Co Humanized antibodies reactive with gpiib/iiia
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
GB9401448D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2261291A1 (en) 1996-07-18 1998-01-29 Csl Limited Pasteurization of immunoglobulin solutions
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
JP3679406B2 (ja) 1998-05-20 2005-08-03 協和醗酵工業株式会社 遺伝子組換え抗体
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
US6610206B1 (en) 1998-10-20 2003-08-26 Advanced Renal Technologies Buffered compositions for dialysis
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
NZ583002A (en) 1999-02-03 2011-12-22 Amgen Inc Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation
ATE251466T1 (de) 1999-04-08 2003-10-15 Genentech Inc Zusammensetzung auf basis gegensätzlich geladener polypeptide
ATE401908T1 (de) 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
NZ535205A (en) 1999-10-04 2006-01-27 Chiron Corp Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions
US20010031260A1 (en) 1999-12-14 2001-10-18 Genentech, Inc. Treatment method
MXPA02006027A (es) 1999-12-16 2002-12-05 Amgen Inc Moleculas tipo osteoprotegerina/receptor del factor de necrosis de tumor y usos de las mismas.
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
DK1666052T3 (da) 2000-02-16 2011-09-12 Genentech Inc Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
WO2002008417A1 (fr) 2000-07-25 2002-01-31 Takeda Chemical Industries, Ltd. Procede de production d'une proteine de recombinaison
WO2002011753A1 (en) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
AU2001277781A1 (en) 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
AU2608602A (en) 2000-12-14 2002-06-24 J Yun Tso Silensed anti-cd28 antibodies and use thereof
US6693173B2 (en) 2000-12-26 2004-02-17 Alpha Therapeutic Corporation Method to remove citrate and aluminum from proteins
ZA200305995B (en) 2001-01-05 2004-08-04 Pfizer Antibodies to insulin-like growth factor I receptor.
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
WO2002068455A2 (en) 2001-02-23 2002-09-06 Immunex Corporation Efficient recovery of correctly refolded proteins
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CN1650393A (zh) 2001-06-25 2005-08-03 皇家菲利浦电子有限公司 高压气体放电灯及其制造方法
PH12012502439A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2456648C (en) * 2001-08-23 2011-08-16 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
CA2452288A1 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
US20030143603A1 (en) 2001-11-30 2003-07-31 Jill Giles-Komar Anti-TNF antibodies, compositions, methods and uses
DE60231651D1 (de) 2001-12-21 2009-04-30 Immunex Corp Proteinreinigungsverfahren
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US20030202975A1 (en) 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
HUE031630T2 (en) * 2002-02-27 2017-07-28 Immunex Corp Stabilized TNFR-Fc containing arginine
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
DE10218570B4 (de) 2002-04-26 2007-10-18 Lohmann Gmbh & Co Kg Acrylatcopolymere und daraus erhältliche Haftklebemassen zum Verkleben von niederenergetischen Oberflächen sowie ihre Verwendung
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2003251592A1 (en) 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
CA2800126A1 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004042012A2 (en) 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
PL383616A1 (pl) 2002-12-20 2008-04-14 Amgen Inc. Środki wiążące inhibitujące miostatynę
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
EP3178492A1 (en) 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
JP4850709B2 (ja) 2003-05-14 2012-01-11 ダニスコ・ユーエス・インコーポレーテッド 反復配列タンパク質ポリマーを使用する、活性剤の制御放出
CA2519875C (en) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP2007522157A (ja) 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
WO2005095454A1 (en) 2004-03-25 2005-10-13 Diadexus, Inc. Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk
CN103393601A (zh) 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
JPWO2006003999A1 (ja) 2004-07-05 2008-07-31 財団法人化学及血清療法研究所 ヒト抗ヒトｂ７ｒｐ−１抗体およびその抗体フラグメント
US7648742B2 (en) * 2004-07-29 2010-01-19 Merck Patent Gmbh Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006064373A2 (en) 2004-12-16 2006-06-22 Genzyme Polyclonals S.A.S. Methods of purifying immunologlobulins
JP4498939B2 (ja) 2005-02-01 2010-07-07 東京応化工業株式会社 ポジ型レジスト組成物およびレジストパターン形成方法
US8597709B2 (en) 2005-04-12 2013-12-03 Inovobiologic Inc. Dietary supplement and methods of use
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070049732A1 (en) 2005-09-01 2007-03-01 Zurlo Eugene J Ultra-high yield intravenous immune globulin preparation
US8877281B2 (en) 2005-09-21 2014-11-04 Burcon Nutrascience (Mb) Corp. Preparation of canola protein isolate involving isoelectric precipitation
US8067350B2 (en) 2005-12-15 2011-11-29 Kimberly-Clark Worldwide, Inc. Color changing cleansing composition
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US20080161242A1 (en) 2006-09-15 2008-07-03 Randolph Theodore W High pressure treatment of proteins for reduced immunogenicity
MX2009004351A (es) 2006-10-27 2009-05-12 Abbott Biotech Ltd Anticuerpos anti-htnfalfa cristalinos.
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
EP3189831A1 (en) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009099641A2 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
US8052645B2 (en) 2008-07-23 2011-11-08 Avant Medical Corp. System and method for an injection using a syringe needle
US8177749B2 (en) 2008-05-20 2012-05-15 Avant Medical Corp. Cassette for a hidden injection needle
AU2009249027C1 (en) 2008-05-20 2015-01-22 Avant Medical Corp. Autoinjector system
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
MX345226B (es) * 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
CN102414221A (zh) 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
US9084849B2 (en) 2011-01-26 2015-07-21 Kaleo, Inc. Medicament delivery devices for administration of a medicament within a prefilled syringe
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
AR088379A1 (es) * 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones metalicos
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
CA2878194C (en) 2012-07-05 2021-06-22 Unitract Syringe Pty Ltd Automatic injectors for injectable cartridges and drive control mechanisms therefor
JP6271536B2 (ja) * 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
EA031324B1 (ru) * 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
EP2919801B1 (en) * 2012-10-26 2020-04-29 Lupin Atlantis Holdings, SA Stable pharmaceutical composition of the tnfr:fc fusion protein etanercept
US9649383B2 (en) 2012-11-19 2017-05-16 Merck Sharp & Dohme Corp. Liquid formulations for TNFR:Fc fusion proteins
KR101419884B1 (ko) * 2012-11-27 2014-07-16 (주)알테오젠 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
AR094458A1 (es) 2012-12-06 2015-08-05 Iams Co Alimento con formas perceptibles para mascotas
WO2014106116A2 (en) 2012-12-28 2014-07-03 Abbott Cardiovascular Systems Inc. Delivery of biologic therapeutics
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
BR112015027764A2 (pt) * 2013-05-02 2017-08-29 Mabxience S A Formulações alternativas para os polipeptídeos de fusão de tnfr: fc
CN113350278B (zh) 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
WO2015080513A1 (en) 2013-11-29 2015-06-04 Hanwha Chemical Corporation A liquid formulation of a fusion protein comprising tnfr and fc region
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
JP6752777B2 (ja) 2014-08-28 2020-09-09 ユーエヌエル ホールディングス エルエルシーＵＮＬ Ｈｏｌｄｉｎｇｓ ＬＬＣ 薬剤送達デバイス用センサシステム
WO2016033496A1 (en) 2014-08-28 2016-03-03 Unitract Syringe Pty Ltd Skin sensors for drug delivery devices
CA2970577A1 (en) * 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
WO2016149139A1 (en) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
US9763976B1 (en) 2016-08-02 2017-09-19 Zo Skin Health, Inc. Composition and method for treating skin conditions
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same

Also Published As

Publication number Publication date
US11491223B2 (en) 2022-11-08
CN109982685A (zh) 2019-07-05
EP3528787A4 (en) 2020-05-06
KR102446838B1 (ko) 2022-09-26
US12214013B2 (en) 2025-02-04
JP6884858B2 (ja) 2021-06-09
JP7754903B2 (ja) 2025-10-15
KR102413592B1 (ko) 2022-06-27
US20250134958A1 (en) 2025-05-01
EP3528787B1 (en) 2026-01-07
KR20190071760A (ko) 2019-06-24
CN114917185A (zh) 2022-08-19
CL2019001053A1 (es) 2019-08-02
CN109982685B (zh) 2022-03-11
US20230080571A1 (en) 2023-03-16
JP2024010026A (ja) 2024-01-23
JP2021120393A (ja) 2021-08-19
CA3040899A1 (en) 2018-04-26
EP3528787A1 (en) 2019-08-28
JP7402195B2 (ja) 2023-12-20
CN114917185B (zh) 2023-11-14
AU2017345490B2 (en) 2022-07-07
BR112019007858A2 (pt) 2019-07-02
US20190022217A1 (en) 2019-01-24
IL266132B (en) 2021-12-01
SG11201903521XA (en) 2019-05-30
US10307483B2 (en) 2019-06-04
KR20210158878A (ko) 2021-12-31
JP2019533679A (ja) 2019-11-21
US20180256718A1 (en) 2018-09-13
JP2026004430A (ja) 2026-01-14
IL266132A (en) 2019-06-30
AU2017345490A1 (en) 2019-05-09
WO2018075818A1 (en) 2018-04-26
US20180110856A1 (en) 2018-04-26
EA201990998A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EP4279071A3 (en) Novel cannabinoid formulations
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MY191581A (en) Anti-pd-1 antibodies
MX2016013486A (es) Activadores de canales ionicos y metodos de uso.
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2019005855A (es) Formulaciones que se pueden pulverizar.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12016501472B1 (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
ZA202102816B (en) High concentration protein formulation
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
PH12020551618A1 (en) Erenumab compositions and uses thereof
JOP20200126A1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
IN2014CH00840A (es)
EP3393459A4 (en) COMPOSITIONS OF A FLUORO CARBON NANOEMULSION, PROCESS FOR THE PREPARATION AND USE THEREOF
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
EP4582145A3 (en) Solid state forms of ixazomib citrate